Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases

Biomedicines, Год журнала: 2024, Номер 12(12), С. 2729 - 2729

Опубликована: Ноя. 28, 2024

Cardiovascular disease (CVD) and ischemic stroke (IS) are the primary causes of mortality worldwide. Hypercholesterolemia has been recognized as an independent risk factor for CVD IS. Numerous clinical trials have unequivocally demonstrated that reducing levels low-density lipoprotein cholesterol (LDL-C) significantly mitigates both cardiac cerebral vascular events, thereby enhancing patient prognosis. Consequently, LDL-C reduction remains a pivotal therapeutic strategy However, despite intensive statin therapy, significant proportion high-risk hypercholesterolemic patients fail to achieve sufficient reductions in levels. In response this challenge, inhibitor targeting proprotein convertase subtilisin-kexin type 9 (PCSK9) developed intervention hyperlipidemia. randomized controlled (RCTs) conclusively combination PCSK9 inhibitors statins enhances prognosis not only with CVD, but also those afflicted symptomatic intracranial artery stenosis (sICAS). reduce by binding molecule preventing its interaction LDLRs. This prevents degradation receptor increases uptake LDL-C, decreasing concentration blood. Besides levels, demonstrate anti-inflammatory anti-atherosclerotic properties while promoting plaque stabilization inhibiting platelet aggregation thrombosis. article aims provide comprehensive review based on relevant literature regarding evolving understanding pleiotropic effects associated inhibitors, particularly focusing their impact cardiovascular system central nervous system.

Язык: Английский

Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future

American Journal of Cardiovascular Drugs, Год журнала: 2024, Номер unknown

Опубликована: Дек. 20, 2024

Язык: Английский